Pregnancy registry for outcomes after tralokinumab exposure
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tracks pregnancy and baby outcomes in people who have been pregnant while taking tralokinumab, a medication for eczema. It compares those outcomes to other eczema treatment groups to help doctors understand potential risks or reassuring effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be pregnant right now when you join the study.
- You must live in the US or Canada.
- You must have an eczema diagnosis (AD) at the time you enroll.
- You must agree to consent to participate and to share key medical information.
- If you were exposed to medications during pregnancy, your exact timing and treatments must fit one of the study’s groups.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at women who used a topical eczema cream called ruxolitinib (Opzelura) or steroid creams during pregnancy. The goal is to compare pregnancy outcomes and baby health up to one year after birth.
This study tests an investigational shot (tralokinumab) plus a steroid cream for children with moderate-to-severe eczema that hasn't been controlled by creams alone. It aims to see if the combination is safe and works better than the cream alone.
This study compares the health of mothers and their babies in two groups: women with eczema who used ruxolitinib cream during pregnancy and those who did not. It aims to see if the cream is safe for both mother and child.
This is an observational study that looks back at medical and pharmacy records of women with atopic dermatitis around pregnancy. It may help researchers better understand how this condition affects pregnant patients and pregnancy-related care.
This study is a long-term registry for adolescents and adults with atopic dermatitis (eczema) who are starting or switching to a systemic medication (a drug that works throughout the body). It will track how these treatments work in real life and how patients feel over time.
This study is a registry for people with eczema (atopic dermatitis) who are under 26 and have taken or plan to take body-wide treatments like pills or injections. By joining, you help researchers track how these treatments work over time.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.